• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Boniva (ibandronate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Boniva (ibandronate)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Boniva (ibandronate sodium) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. In osteoporosis, where osteoclasts break down bone too quickly, inhibition of this pathway has been shown to slow bone turnover, leading to not only an attenuation of turnover but also a mean increase in bone mass.

    Boniva is specifically indicated for the treatment and prevention of osteoporosis in postmenopausal women. The recommended dose of Boniva is 2.5 mg (oral tablet) once daily.

    Boniva is approved as a once-daily oral tablet, with a recommended dosage of 2.5 mg.

    Update: In March 2005, Boniva received approval in a new formulation, as a once-monthly oral tablet, with a recommended dosage of 150 mg on the same date each month. This approval made Boniva the first ever once-monthly oral treatment for any chronic disease.

    Clinical Results

    Treatment Study
    FDA approval of Boniva for the treatment of osteoporosis was based on a three-year, randomized, double blind, placebo-controlled, multinational pivotal phase III trial, called BONE. The study enrolled 2,946 post-menopausal women between age 55 and 80 years with osteoporosis. Subjects were treated with either placebo or one of two oral ibandronate schedules: daily (2.5 mg) or intermittent (20 mg) taken every other day for 24 days followed by a between-dose interval of greater than two months. All participants received daily oral calcium (500 mg) and vitamin D (400 IU) supplementation. The main outcome measure was the occurrence of new radiographically diagnosed fractured of the vertebrae after 3 years of treatment.

    Results showed that 2.5mg daily of ibandronate reduced the risk of new vertebral fractures by 62% compared with placebo. In addition, data demonstrated an intermittent (20mg) dose of oral ibandronate taken every other day for 24 days reduced the risk of new vertebral fractures by 50% compared with placebo. The cumulative incidence of vertebral fractures in the placebo group was 9.6% over three years, 4.7% in the 2.5mg daily group and 4.9% in the 20mg intermittent group. In the study, ibandronate demonstrated a favorable tolerability profile, with the most commonly reported adverse events being upper respiratory tract infection, back pain, arthralgia, dyspepsia and bronchitis. The percentage of subjects who withdrew from the study due to adverse events was approximately 18% in each of the three groups.

    Prevention Study FDA approval of Boniva for the prevention of osteoporosis was based on a randomized, double blind, placebo controlled, two year trial. The study enrolled 653 postmenopausal women aged 41 to 82 years of age without osteoporosis. Subjects were given Boniva at .5 mg, 1.0 mg and 2.5 mg or placebo. All subjects were given 500 mg of supplemental calcium daily. The primary endpoint was the change in bone mineral density (BMD) of the lumbar spine after two years of treatment.

    Results showed that treatment with 2.5 mg daily of Boniva achieved a mean increase in lumbar spine BMD of 3.1% compared with placebo after two years of treatment. Data also showed that Boniva (2.5 mg daily) achieved an increase in hip BMD by 1.8%, the femoral neck by 2.0% and the trochanter by 2.1%.

    Update: Once-Monthly Dosing Study
    Approval of the once-monthly dosing formulation was based on a 12-month, double-blind, placebo controlled noninferiority study which compared the safety and efficacy of the 150 mg once-monthly dose of Boniva to the approved 2.5 mg once-daily dose. The trial enrolled 1602 postmenopausal women with low BMD due to confirmed osteoporosis, who were randomized to receive one of the two regimens. Primary efficacy data indicated that the once-monthly dose produced a mean increase in BMD of 4.85%, vs. an increase of 3.86% for the daily dose. This 0.99% relative increase exceeded the non-inferiority endpoint, establishing the once-monthly regimen's statistical superiority in improving BMD (p=0.002).

    Side Effects

    Adverse events associated with the use of Boniva may include (but are not limited to) the following:


    • Dyspepsia
    • Diarrhea
    • Tooth Disorder
    • Vomiting
    • Gastritis
    • Allergic Reaction
    • Infection

    Update: Results from a 1 year trial comparing the safety of once monthly Boniva to the approved daily regimen produced similar tolerability profiles. Serious events occurred in 7.1% or subjects in the once-monthly group, compared to 4.8% in the daily group. Overall adverse events which may occur more often with once-monthly dosing vs. once daily include, but are not limited to, the following:


    • Constipation
    • Influenza-like Illness
    • Pain in the extremities

    Mechanism of Action

    Boniva has a high binding affinity for hydroxypatite, a calcium compound which is part of the mineral matrix of bone. Binding to the site allows the drug to be taken up by mature osteoclasts during the resorption process, and it appear to act intracellularly as an isoprenoid diphosphate lipid analogue, disrupting the farnesylation and geranylgeranylation of small GTPase signaling proteins and potentiating selective osteoclast apoptosis.

    Literature References

    Muller R, Hannan M, Smith SY, Bauss F. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. Journal of Bone Mineral Research. 2004 Nov;19(11):1787-96. Epub 2004 Aug 16.

    Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Current Pharmaceutical Design. 2003;9(32):2643-58

    Coleman RE, Purohit OP, Black C, Vinholes JJ, et al. Double-blind, randomised, placebo-controlled study of oral ibandronate in patients with metastatic bone disease. Annals of Oncology 1999;10:311-16

    Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Journal of Clinical Oncology 1996;14:268-76

    Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. British Journal of Cancer 1997;73:293-300

    Additional Information

    For additional information regarding Boniva or osteoporosis, please visit the Boniva web page.

    Company Name: Roche / GlaxoSmithKline
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing